Effects of Schedule I drug laws on neuroscience research and treatment innovation

@article{Nutt2013EffectsOS,
  title={Effects of Schedule I drug laws on neuroscience research and treatment innovation},
  author={David J. Nutt and Leslie A King and David E. Nichols},
  journal={Nature Reviews Neuroscience},
  year={2013},
  volume={14},
  pages={577-585}
}
Many psychoactive drugs are used recreationally, particularly by young people. This use and its perceived dangers have led to many different classes of drugs being banned under national laws and international conventions. Indeed, the possession of cannabis, 3,4-methylenedioxy-N-methylamphetamine (MDMA; also known as ecstasy) and psychedelics is stringently regulated. An important and unfortunate outcome of the controls placed on these and other psychoactive drugs is that they make research into… Expand
Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use
Psychedelic drugs have been used as treatments in indigenous cultures for thousands of years. Yet, due to their legal status, there has been limited scientific research into the therapeutic potentialExpand
Psychedelic drugs—a new era in
psychiatry?

  • D. Nutt
  • Medicine
  • Dialogues in clinical neuroscience
  • 2019
TLDR
The renaissance of classical psychedelic drugs such as psilocybin and LSD plus 3,4-methylene dioxymethamphetamine (MDMA—ecstasy) in psychiatric research is covered, which is likely to see these medicines approved for clinical practice soon afterwards. Expand
Can Neuroscience Improve Addiction Treatment and Policies?
TLDR
How more informed understanding of neuroscience may help to improve the effectiveness and reduce the unintended side effects of contemporary drug policies is explored and some rational ways neuroscience may better inform and assist in policy decisions are suggested. Expand
Abuse of New Psychoactive Substances: Threats and Solutions
There has been an explosive increase in the non-medical use of so-called ‘designer drugs’ or ‘new psychoactive substances’ (NPS), which are synthetic alternatives to illicit drugs of abuse (BaumannExpand
Psychiatry & the psychedelic drugs. Past, present & future
TLDR
Clinical trials using psychedelics pre and post prohibition are summarised, the methodological challenges of performing good quality trials in this area are discussed, and a strategic approach to the legal and regulatory barriers to licensing psychedelics as a treatment in mainstream psychiatry is considered. Expand
Legal controls on cannabimimetics: an international dilemma?
  • L. King
  • Medicine, Engineering
  • Drug testing and analysis
  • 2014
TLDR
The growing interest in the clinical potential of tetrahydrocannabivarin (THCV) is inhibited, at least in the UK, by its unintended status as a Schedule 1 substance, and the generic definition of classical cannabinoids shows signs of weakness. Expand
Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy
The potential of psychedelic drugs in the treatment of mental health problems is increasingly being recognized. However, relatively little thrust has been given to the suggestion that individualsExpand
Keep off the grass? Cannabis, cognition and addiction
TLDR
The current state of knowledge about vulnerability factors, the variations in types of cannabis, and the relationship between these and cognition and addiction are reviewed. Expand
Does cannabidiol have a role in the treatment of schizophrenia?
TLDR
It is argued that further research on CBD is required to fast-track its progress to the clinic and in doing so, it may generate novel insights into the neurobiology of schizophrenia. Expand
Studies with psychedelic drugs in human volunteers
TLDR
The range of hallucinogens suggest that they are distinct pharmacologic agents and will not be equally safe or effective in therapeutic targets, and newly synthesized specific and selective agents modeled on the legacy agents may be worth considering. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 67 REFERENCES
MDMA (Ecstasy).
  • R. El-Mallakh, H. D. Abraham
  • Medicine
  • Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2007
TLDR
MDMA is an important drug of abuse that has a wide range of adverse consequences and there is a dearth of treatment strategies for both acute intoxication and consequences of longer term use. Expand
Human hallucinogenic drug research in the United States: a present-day case history and review of the process.
  • R. Strassman
  • Political Science, Medicine
  • Journal of psychoactive drugs
  • 1991
TLDR
This article reviews the application process, obstacles and their solutions, and the local and federal issues involved of N,N-dimethyltryptamine (DMT) to humans. Expand
Can drugs be used to enhance the psychotherapeutic process?
Many preindustrial cultures traditionally use certain psychedelic plants to enhance a procedure that resembles psychotherapy--an idea that was also tested in Western psychiatry in the 1950s andExpand
State of the art treatments for cannabis dependence.
TLDR
There is a need for a continuing care model with long-term follow-up that extends past the periods typically evaluated in treatment studies and for further investigation of genetic underpinnings and endophenotypes underlying cannabis dependence to identify neurobiological mechanisms for targeted intervention. Expand
Severe Dopaminergic Neurotoxicity in Primates After a Common Recreational Dose Regimen of MDMA ("Ecstasy")
TLDR
Nonhuman primates exposed to several sequential doses of MDMA, a regimen modeled after one used by humans, developed severe brain dopaminergic neurotoxicity, in addition to less pronounced serotonergic neurot toxicity, which has implications for mechanisms of MDMA neurotoxicity. Expand
Equasy — An overlooked addiction with implications for the current debate on drug harms
  • D. Nutt
  • Medicine
  • Journal of psychopharmacology
  • 2009
TLDR
In this study, this study assessed alcohol, tobacco and some other misused substances to provide anchor points that would allow non-experts and the general public to better understand the harms of drugs with which they might not have familiarity. Expand
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
TLDR
The idea that high-THC/low-CBD cannabis products are associated with increased risks for mental health is supported, and pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment is tested. Expand
Using dopamine research to generate rational cannabinoid drug policy.
TLDR
A review of neuroscience research suggests that synthetic CBs that act like Δ⁹-tetrahydrocannabinol (THC) by directly binding to and stimulating CB receptors, as well as novel drugs that indirectly stimulate these receptors by increasing levels of endogenous CB neurotransmitters have therapeutic value. Expand
Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation?
TLDR
It is argued that increased policing of cannabis use under the current drug classification system will lead to increased criminalization of young people, but is unlikely to significantly reduce the rates of schizophrenia and psychosis. Expand
Methoxetamine: from drug of abuse to rapid-acting antidepressant.
TLDR
The hypothesis is that methoxetamine can produce rapid antidepressant effects in patients with resistant and non-resistant unipolar and bipolar depression. Expand
...
1
2
3
4
5
...